Change of Auditor

RNS Number : 1693V
Alliance Pharma PLC
08 August 2022
 

 

For immediate release

8 August 2022

 

Icon Description automatically generated with low confidence

 

 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

 

Change of Auditor

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, following a tender process, it has appointed Deloitte LLP ("Deloitte") as its auditor for the financial year ending 31 December 2022. KPMG LLP ("KPMG"), its outgoing auditor of six years, did not participate in this tender process.

 

KPMG has submitted to the Company, in accordance with section 519 of the Companies Act 2006, a letter stating its reason for resigning. A copy of KPMG's letter has, in accordance with section 520 of the Companies Act 2006, today been sent to all shareholders, along with an explanatory letter from the Company. Both letters can be found at this link:

https://www.alliancepharmaceuticals.com/media/gdgnqciv/circular-080822.pdf

 

Any proposal to re-appoint Deloitte as auditor for the financial year ending 31 December 2023 will be subject to approval by the Group's shareholders at the Company's Annual General Meeting to be held in 2023.

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

 

 

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

 

alliancepharma@buchanan.uk.com

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith

 

Corporate Broking: James Black

 

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams

 

Corporate Broking: Patrick Robb

 

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website www.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPBIGDILXGDGDR
UK 100

Latest directors dealings